The US Food and Drug Administration has approved Natazia, a combination hormonal oral contraceptive from Bayer HealthCare Pharmaceuticals.

The drug contains oestrogen and progestin and is the first four-phasic oral contraceptive drug marketed in the US.

The safety and efficacy of Natazia had been evaluated in two multi-centric phase III trials in Europe and North America involving 1,867 women and nearly 30,000, 28-day treatment cycles.

Nearly 12 million women in the US and over 100 million women worldwide use oral contraceptives.